iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Stock Price Down 1.3% – Should You Sell?

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) traded down 1.3% during mid-day trading on Tuesday . The stock traded as low as $21.48 and last traded at $21.78. 17,987 shares changed hands during trading, a decline of 41% from the average session volume of 30,319 shares. The stock had previously closed at $22.06.

iShares Genomics Immunology and Healthcare ETF Price Performance

The stock’s 50-day moving average is $22.57 and its 200 day moving average is $23.61. The stock has a market cap of $112.17 million, a price-to-earnings ratio of 23.93 and a beta of 1.03.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in iShares Genomics Immunology and Healthcare ETF stock. Avior Wealth Management LLC purchased a new position in shares of iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 9,500 shares of the company’s stock, valued at approximately $234,000. Avior Wealth Management LLC owned approximately 0.16% of iShares Genomics Immunology and Healthcare ETF at the end of the most recent reporting period.

iShares Genomics Immunology and Healthcare ETF Company Profile

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.